Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
VAPOTHERM INC (VAPO)
|
Add to portfolio |
|
|
|
| Price: |
$20.72
| | Metrics |
| OS: |
49.1
|
M
| |
|
|
| Market cap: |
$1.02
|
B
| |
|
|
|
Net cash:
|
$18
|
M
| |
$0.37
|
per share
|
|
EV:
|
$999
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($670.0)
|
k
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 |
| Revenues | 66.8 | 113.3 | 125.7 | 48.1 | 42.4 | 35.6 | 30.1 |
| Revenue growth | -41.0% | -9.9% | 161.4% | 13.5% | 19.0% | 18.2% | |
| Cost of goods sold | 49.6 | 60.1 | 62.7 | 26.8 | 25.6 | 22.4 | 20.2 |
| Gross profit | 17.2 | 53.2 | 63.0 | 21.3 | 16.8 | 13.2 | 9.9 |
| Gross margin | 25.8% | 46.9% | 50.1% | 44.3% | 39.6% | 37.2% | 33.0% |
| Sales and marketing | 46.1 | 60.1 | 65.1 | 37.7 | 33.9 | 26.2 | 20.0 |
| Research and development | | | 17.0 | 13.4 | 8.8 | 7.6 | 6.2 |
| General and administrative | | | 24.0 | 18.4 | 11.2 | | |
| EBITA | -50.5 | 3.6 | -42.8 | -47.0 | -37.2 | -28.6 | -22.2 |
| EBITA margin | -75.6% | 3.2% | -34.1% | -97.7% | -87.9% | -80.3% | -73.8% |
| Amortization of intangibles | 0.4 | 0.6 | 0.2 | | | | |
| EBIT | -50.8 | 2.9 | -43.0 | -47.0 | -37.2 | -28.6 | -22.2 |
| EBIT margin | -76.1% | 2.6% | -34.2% | -97.7% | -87.9% | -80.3% | -73.8% |
| Pre-tax income | -113.2 | -59.9 | -51.5 | -51.2 | -42.5 | -31.0 | -23.1 |
| Income taxes | 0.0 | -0.1 | 0.0 | -0.1 | 0.0 | 0.0 | 0.0 |
| Tax rate | | 0.1% | 0.0% | 0.3% | 0.0% | 0.0% | 0.0% |
| Net income | -113.3 | -59.8 | -51.5 | -51.1 | -42.5 | -31.0 | -23.1 |
| Net margin | -169.5% | -52.8% | -41.0% | -106.1% | -100.4% | -87.1% | -76.6% |
| |
| Diluted EPS | ($4.24) | ($2.31) | ($2.16) | ($2.74) | ($14.65) | ($44.82) | ($49.38) |
| Shares outstanding (diluted) | 26.7 | 25.9 | 23.8 | 18.6 | 2.9 | 0.7 | 0.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|